1. Mattson J, Simon M. The Pioneers of NMR and Magnetic Resonance in Medicine: The Story of MRI. Dean Book Co., Bar-Ilan University Press; 1996.
2. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging;Marckmann;J Am Soc Nephrol,2006
3. American College of Radiology. Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, Version 10.3. Available from: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. [Last accessed on 2019 Sep 20].
4. European Medicines Agency. Questions and Answers on the Review of Gadolinium-Containing Contrast Agents; 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500015635. [Last accessed on 2018 May 26].
5. Gadolinium-Based Contrast Agents & Nephrogenic Systemic Fibrosis FDA Briefing Document. Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committee; 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM190850.pdf. [Last accessed on 2018 May 26].